Search
PIK3CA
go.drugbank.com/drugs/DB14954InvestigationalPIK3CA is under investigation in clinical trial NCT02957266 (Cervical Cancer Radiotherapy by Use of VMAT, Individualized Polyradiosensitization and Interstitial Brachytherapy).
Afimoxifene
go.drugbank.com/drugs/DB04468InvestigationalIt is being developed by Ascent Therapeutics.
Flurbiprofen axetil
go.drugbank.com/drugs/DB14938InvestigationalFlurbiprofen axetil is under investigation in clinical trial NCT02043366 (Effect of Butorphanol Combined With Flurbiprofen Axetil on Preventing Hyperalgesia Induced by Remifentanil in Patients).
LY3884961
go.drugbank.com/drugs/DB17070InvestigationalLY3884961 (previously PR001) is being developed by Prevail Therapeutics as a single-dose gene therapy for patients with Parkinson's disease and Gaucher disease.[L43468]
MBP-091
go.drugbank.com/drugs/DB17741ExperimentalMBP-091 is a monoclonal antibody being investigated for the treatment of Marburg virus disease (MVD) caused by infection with Marburg virus (MARV).[L46212]
Hypoxanthine
go.drugbank.com/drugs/DB04076InvestigationalHypoxanthine is a purine and a reaction intermediate in the metabolism of adenosine and in the formation of nucleic acids by the salvage pathway.
Vicadrostat
go.drugbank.com/drugs/DB21693InvestigationalVicadrostat is under investigation in clinical trial NCT07064473 (A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular
S-40503
go.drugbank.com/drugs/DB13938ExperimentalS-40503 is an investigational selective androgen receptor modulator (SARM) developed for the treatment of osteoporosis by the Japanese company Kaken Pharmaceuticals.
AAV-dXIAP
go.drugbank.com/drugs/DB17880ExperimentalAAV-dXIAP is a recombinant adeno-associated virus-encoded gene for X-linked mammalian inhibitor of apoptosis protein (XIAP) developed by Neurologix.
Alintegimod
go.drugbank.com/drugs/DB18879InvestigationalAlintegimod is under investigation in clinical trial NCT06362369 (A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy).